Literature DB >> 22541615

Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer.

Diana M Tacelosky1, Amy E Creecy, Sriram S Shanmugavelandy, Jill P Smith, David F Claxton, James H Adair, Mark Kester, Brian M Barth.   

Abstract

Photodynamic therapy (PDT) has emerged as an alternative modality for cancer treatment. PDT works by initiating damaging oxidation or redox-sensitive pathways to trigger cell death. PDT can also regulate tumor angiogenesis and modulate systemic antitumor immunity. The drawbacks to PDT--photosensitizer toxicity, a lack of selectivity and efficacy of photosensitizers, and a limited penetrance of light through deep tissues--are the same pitfalls associated with diagnostic imaging. Developments in the field of nanotechnology have generated novel platforms for optimizing the advantages while minimizing the disadvantages of PDT. Calcium phosphosilicate nanoparticles (CPSNPs) represent an optimal nano-system for both diagnostic imaging and PDT. In this review, we will discuss how CPSNPs can enhance optical agents and serve as selective, non-toxic, and functionally stable photosensitizers for PDT. We will also examine novel applications of CPSNPs and PDT for the treatment of leukemia to illustrate their potential utility in cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541615

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  2 in total

1.  PhotoImmunoNanoTherapy reveals an anticancer role for sphingosine kinase 2 and dihydrosphingosine-1-phosphate.

Authors:  Brian M Barth; Sriram S Shanmugavelandy; James M Kaiser; Christopher McGovern; Erhan İ Altınoğlu; Jeremy K Haakenson; Jeremy A Hengst; Evan L Gilius; Sarah A Knupp; Todd E Fox; Jill P Smith; Timothy M Ritty; James H Adair; Mark Kester
Journal:  ACS Nano       Date:  2013-02-14       Impact factor: 15.881

2.  Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.

Authors:  Welley S Loc; Samuel S Linton; Zachary R Wilczynski; Gail L Matters; Christopher O McGovern; Thomas Abraham; Todd Fox; Christopher M Gigliotti; Xiaomeng Tang; Amra Tabakovic; Jo Ann Martin; Gary A Clawson; Jill P Smith; Peter J Butler; Mark Kester; James H Adair
Journal:  Nanomedicine       Date:  2017-07-01       Impact factor: 5.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.